INTRODUCTION
SAB is a severe infection known for its high morbidity and is associated with a 30-day overall mortality of 20% (1). An important complication of SAB is metastatic infection, with a reported incidence between 16 and 68% (2-7). Known risk factors for development of metastatic infection in SAB patients are community acquisition of the bacteremia, signs of infection present for more than 48 hours before initiation of appropriate antibiotic treatment, fever more than 72 hours after initiation of appropriate antibiotic treatment, and positive blood cultures more than 48 hours after initiation of appropriate antibiotic treatment (3) . Early detection of metastatic infection is crucial, as morbidity and mortality are higher in the presence of these foci, probably due to incomplete eradication during treatment (8) . However, metastatic infectious foci are often asymptomatic. In up to one-third of patients with Gram-positive bacteremia and metastatic foci, localizing signs and symptoms are absent (8) .
During the past years, 18 F-fluorodeoxyglucose positron emission tomography combined with computed tomography ( 18 F-FDG-PET/CT) has been extensively used in diagnosing infectious diseases.
Previous studies on the value of 18 F-FDG-PET/CT in metastatic infection have demonstrated that 18 F-FDG-PET/CT detects infectious foci in patients with bacteremia or infective endocarditis and leads to a decrease in relapse and mortality rate (9, 10) . Furthermore, 18 F-FDG-PET/CT has shown to be cost-effective in patients with Gram-positive bacteremia (11) . The previous studies, however, did not report on how 18 F-FDG-PET/CT optimizes treatment in SAB, while the positive effect on outcome is undoubtedly caused by treatment modification. Therefore, the aim of this study was to investigate the diagnostic value of 18 F-FDG-PET/CT for newly diagnosed metastatic infection, subsequent treatment modifications, and outcome in patients with SAB, with a focus on patients with high-risk bacteremia.
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MATERIALS AND METHODS

Study design and patients
This retrospective cohort study was performed at Radboud university medical center, Nijmegen, the Netherlands. All consecutive adult SAB cases between January 2013 and April 2016 were included. SAB was defined as one or more blood cultures positive for S. aureus. SAB cases were designated hospital-acquired if patients had been admitted for at least 48 hours before the first positive blood culture, or as community acquired in all other cases. Exclusion criteria were pregnancy, and death within 48 hours after the first positive blood culture with S. aureus. According to the Dutch law, this study was exempt from approval by an ethics committee, because of the retrospective character of this study and the anonymous processing of data.
The regional institutional review board approved this retrospective study and the requirement to obtain informed consent was waived.
Data collection
We reviewed the medical records of all patients and collected data on patient demographic characteristics, estimated prognosis of preexisting underlying disease and comorbidity according to the Charlson comorbidity score (12) , onset of bacteremia, presence of intravascular catheters or foreign body material, resistance of S. aureus to methicillin, foci of infection, and clinical parameters at SAB onset, diagnostic investigations, antimicrobial therapy, and outcomes. The data were retrieved electronically from clinical charts and reports of diagnostic studies (including laboratory, microbiological and imaging data).
Diagnostic work-up
According to definitions established previously (3, 8) , cases were designated high-risk SAB if one of the following criteria for increased risk of metastatic infection were met: community acquisition of the bacteremia, signs of infection for more than 48 hours before initiating of appropriate antibiotic treatment, fever more than 72 hours after initiating of appropriate antibiotic treatment, positive blood cultures more than 48 hours after initiating of appropriate antibiotic treatment, or already confirmed metastatic foci at the moment of presentation. For all patients with high-risk SAB, echocardiography and 18 F-FDG-PET/CT were by Universiteitsbibliotheek Nijmegen on March 27, 2017. For personal use only. jnm.snmjournals.org Downloaded from
recommended.
An integrated PET/CT scanner (Biograph 40 mCT; Siemens Healthcare) was used. Before 18 F-FDG injection, patients fasted and any glucose or insulin-containing infusions were discontinued for at least six hours. In 66.7% of patients, a low carbohydrate fat-allowed diet was performed 24 hours before 18 F-FDG-PET/CT. Blood glucose samples were taken from all patients prior to 18 F-FDG administration. At the time of 18 F-FDG injection, glucose was below 12 mmol/l in all patients, including diabetic patients. One hour after intravenous injection of an average dosage of 3.3 MBq x body weight (kg)/min/bed position 18 F-FDG (Mallinckrodt Pharmaceuticals, Petten, The Netherlands or IBA Molecular, Amsterdam, The Netherlands), a whole body low-dose CT was acquired for anatomic correlation and attenuation correction of the PET data.
Emission images of the same area were acquired. 18 F-FDG-PET/CT scans were considered abnormal if focal accumulation of 18 F-FDG was detected. Normal test results were considered true-negative when no complicating infectious foci were diagnosed within two weeks after 18 F-FDG-PET/CT was performed. Normal test results were considered false-negative when a localized infectious focus was diagnosed but not reported on 18 F-FDG-PET/CT. Abnormal test results not related to metastatic infection that were caused by a confirmed alternative diagnosis (i.e. cancer) were categorized as non-infectious relevant.
In all patients with SAB, the local antimicrobial stewardship program recommends bedside consultation by an infectious disease specialist (ID specialist), as well as echocardiography. Transthoracic echocardiography (TTE) was used as a first-line screening technique, except for those patients with prosthetic valves, in whom transesophageal echocardiography (TEE) was the first-line technique. TEE was recommended in all patients in whom TTE was negative for endocarditis, especially when imaging was hampered by technical or anatomical problems. Endocarditis was defined according to the modified Duke criteria (13) .
Patients were treated according to the national guideline for SAB which is concordant with the IDSA guideline (14) . However, for patients with risk factors for metastatic foci but without evidence of endocarditis after echocardiography and without signs of metastatic infection on 18 F-FDG-PET/CT, the institutional guideline recommends antimicrobial therapy for two weeks. These patients were considered as having uncomplicated bacteremia instead of complicated bacteremia.
Diagnosis and patient follow-up
Patient outcome and recurrent infection were assessed by reviewing patients' medical records .
Patient follow-up after end of antimicrobial therapy was at least three months in order to capture SAB relapse, mortality, and cause of death. Patients were considered to be cured if no symptoms or signs of infection were present three months after the discontinuation of antibiotic treatment. Relapse of SAB was defined as a second episode of SAB within three months after end of treatment.
F-FDG-PET/CT and treatment modifications
T h e i m p a c t o f 18 F-FDG-PET/CT on treatment was determined by the investigators for all cases in a two step approach. First, treatment duration was determined based on all clinical information available before 18 F-FDG-PET/CT was performed. Second, the results of the 18 F-FDG-PET/CT were provided, and the modifications of therapy based on these results were noted. During a weekly multidisciplinary meeting, all results of 18 F-FDG-PET/CT scans performed in patients with SAB were discussed with a panel of ID specialist and nuclear medicine physicians and treatment modifications based on these results were also noted in the patient's chart.
T h e i m p a c t o f 18 F-FDG-PET/CT on treatment was classified as follows: 1) extension of antibiotic treatment including 1a) prolonged intravenous antibiotic therapy, e.g. instead of oral antibiotic therapy, 1b) addition of a second antimicrobial drug, e.g. rifampin in patients with foreign body material infection, or 1c) extension of total treatment duration, e.g. in case of joint or vascular prosthesis infection, 2) surgical or radiological intervention, e.g. abscess drainage, removal of foreign body material, and 3) shortening of treatment duration. If the results of the 18 F-FDG-PET/CT did not result in any intervention, this was also reported. To prevent interpretation bias, two independent physician observers (MAHB and IJEK) reviewed hospitalization records and determined treatment modification before and after 18 F-FDG-PET/CT results. If there was no consensus, a third independent infectious disease specialist (CPBR) with broad experience in SAB and 18 F-FDG-PET/CT made the final judgment. In patients with high-risk SAB, a comparison was made between patients who underwent 18 F-FDG-PET/CT and patients who did not.
Statistical analysis
by Universiteitsbibliotheek Nijmegen on March 27, 2017. For personal use only. jnm.snmjournals.org Downloaded from 7 SPSS (version 22.0; SPSS, Inc.) was used for analyzing data. Descriptive statistics for continuous variables were represented as median +/-standard deviation. Unpaired student's t tests were used to compare continuous variables. Categorical variables were compared by use of the chi-square test or Fisher's exact test when the chi-square test was not appropriate. Differences were considered to be statistically significant at a two-sided p-value of <0.05. To determine independent predictors of three-month mortality in the high-risk bacteremia group, we performed a multivariate analysis, including prognostic factors associated with a p-value <0.20 in univariate analysis. To limit the amount of variables in the model, the Charlson comorbidity score was used as a composite variable for age and co morbidity. As a composite variable for riskfactors for metastatic infection, a risk score previously described by Fowler et al (3) was used; communityacquisition, persistent fever >72 hours, and skin findings suggesting the presence of metastatic infection were separately scored as 1 point, and positive follow-up blood culture results were scored as 2 points.
RESULTS
During the study period, 195 events of SAB were identified. A total of 11 patients (5.6%) were excluded: 6 patients died within 48 hours, and 5 patients were lost to follow-up. A total of 184 patients were included in the final analysis. Of these, 148 (80.0%) had ≥1 risk factor for metastatic infection, and were classified as high-risk SAB. 18 F-FDG-PET/CT was performed in 99 of 148 (66.9%) high-risk SAB cases. In addition, 18 F-FDG-PET/CT was performed in 6 of 36 (16.7%) patients without risk factors for metastatic infection.
Definite endocarditis according to the modified Duke criteria was diagnosed in 16 patients (8.7%).
Forty-six patients (25.0%) were admitted to the ICU within 24 hours before and one week after SAB onset. Of 184 S. aureus strains isolated, only 5 (2.7%) were methicillin-resistant. Central venous catheter infection was considered responsible for 35 episodes (19.0%) of SAB. Baseline characteristics of all patients with and without 18 F-FDG-PET/CT are shown in Table 1 . after the first blood culture became positive. In 5 of 6 patients without risk factors for metastatic infection in whom 18 F-FDG-PET/CT was performed, no metastatic infection was found on 18 (Table 2) . Of all 73 patients with metastatic infection, 47 patients (64.4%) were diagnosed with metastatic foci in more than one organ system.
Detection of metastatic infection by 18 F-FDG-PET/CT
Eighteen patients had increased 18 F-FDG uptake in a cardiac valve suspected for endocarditis, of whom 5 had a definite endocarditis according to the modified Duke criteria, 10 had a possible endocarditis, and in 3 patients the diagnosis of endocarditis was rejected.
Patient outcome
The relapse rate three months after treatment discontinuation was 2.2% (4/184). Overall threemonth mortality was 18.5% (34/184). In the univariate analysis, age (59 versus 69 years, p <0.05), intensive care admission (22.0% versus 38.2%, p <0.05), Charlson comorbidity score (4.3 versus 6.5, p <0.05), and no 18 F-FDG-PET/CT performed (38.0% versus 64.7%, p=0.005) were significantly different between survivors and non-survivors.
Patients with risk factors for metastatic infection
The group with a risk factor for metastatic infection who did not undergo 18 F-FDG-PET/CT (Risk+/PET-) was compared with the group of patients with a risk factor for metastatic infection and a 18 F-FDG-PET/CT performed (Risk+/PET+) ( Table 3 ). In patients with risk factors for metastatic infection in whom an 18 F-FDG-PET/CT was performed, three-month mortality was significantly lower compared to the 'Risk+/PET-' group (12.1% versus 32.7%, p=0.003). Multivariate analysis of risk factors for three-month Table 4 . 18 F-FDG-PET/CT was the only factor that was significantly associated with reduced mortality (p=0.005; OR, 0.204; 95% confidence interval (CI), 0.066-0.624). A higher co-morbidity score was significantly associated with increased mortality (p=0.003; OR, 1.254; 95% CI, 1.078-1.457).
Treatment modifications in high-risk patients
In the 99 patients with high-risk SAB who underwent 18 F-FDG-PET/CT, 104 treatment modifications were made in 74 patients (74.7%) after the results of 18 F-FDG-PET/CT became available (Table 5 ). In 22 patients (22.2%), more than one treatment modification was made. In 25 patients (25.3%), treatment duration was shortened because no metastatic infection was detected. In 15 patients (15.2%), intravenous antibiotic therapy was prolonged based on the 18 F-FDG-PET/CT results, in 10 patients (10.1%) a second antimicrobial drug was prescribed, and in 35 patients (35.4%), the total treatment duration was extended. In most cases, treatment was extended because of bone or joint involvement (22.2%), vascular prosthesis infection (19.4%), or other endovascular infection (17%). Percutaneous or surgical drainage was performed in 19 patients (19.2%) based on the outcome of 18 F-FDG-PET/CT ( Fig. 1 and Fig. 2 ). No treatment modification was made in 25 patients (25.3%) ( Table 5) .
Of all patients with a planned treatment duration of 6 weeks or more before 18 F-FDG-PET/CT was performed, one or more treatment modifications were performed in 23 out of 46 patients (50.0%) based on 18 F-FDG-PET/CT results (Fig. 3) , compared to 51 out of 53 (96.2%) in the group with a planned treatment duration of less than 6 weeks.
The following relevant diseases not related to SAB were diagnosed in 7 patients (7.1%): pulmonary carcinoma, mediastinal carcinoid tumour, recurrent adenocarcinoma of the rectum, recurrent vaginal carcinoma, benign thyroid adenoma, inflammatory bowel disease, and esophageal candidiasis. Irrelevant findings were found in 8 patients: in these patients two colonoscopies, three esophago-gastroduodenoscopies, three ultrasounds, and one CT-scan were performed without a clear diagnosis.
DISCUSSION
In this study, we investigated the value of 18 F-FDG-PET/CT in patients with SAB for detecting metastatic infection and its role in treatment modification in these patients. In a previous prospective study on 115 patients with high-risk Gram-positive bacteremia (9), the addition of 18 F-FDG-PET/CT to standard care led to significantly more patients who were diagnosed with metastatic infection compared to a matched historical control group of 230 patients in whom no 18 F-FDG-PET/CT was performed (67.8% versus 35.7% in the control group). Furthermore, six-month mortality rate decreased from 32.2% to 19.1% when 18 F-FDG-PET/CT was performed. An explanation for the slightly higher detection level in our study (73.7%) could be the fact that metastatic infection is more often seen in SAB than in other types of Gram-positive bacteremia.
Another study on the value of 18 F-FDG-PET/CT for the diagnosis of metastatic infection in 47 patients with infectious endocarditis found that 18 F-FDG-PET/CT was associated with a twofold reduction in the number of relapses and 18 F-FDG-PET/CT enabled significantly more infectious complications to be diagnosed (57.4% versus 18% in matched controls) (10). Orvin et al. (15) prospectively studied the value of 18 F-FDG-PET/CT in 40 consecutive patients with definite endocarditis according to the Duke criteria. 18 F-FDG-PET/CT demonstrated extracardiac complications in 17 patients (42.5%), and these findings led to a change of treatment in 14 patients (35%) while these patients already had an indication for prolonged antibiotic treatment because of endocarditis. This is comparable to our results, as treatment was still adapted in 50% of patients with an indication for prolonged treatment before 18 F-FDG-PET/CT was performed.
In the present study, the early detection of metastatic infectious foci facilitated the adaptation of treatment in patients at high risk of relapse. The three-month relapse rate was only 2.2%, which is low compared to the rates reported in the literature for complicated SAB (2.1-23%) (16) . An important finding of the present study is that patients with risk factors for metastatic infection who did not undergo 18 F-FDG-PET/CT had a significantly higher mortality rate compared to those who underwent 18 F-FDG-PET/CT (32.7% versus 12.1%, p=0.003), even though the average number of risk factors for metastatic infection in the latter group was higher. This emphasizes the importance of the risk assessment for metastatic infection, and suggests that physicians should not refrain from ordering 18 F-FDG-PET/CT with high-risk SAB based on personal judgment. Early death may be hypothesized to be a confounding factor, as those patients were 18 F-FDG-PET/CT. However, in a sensitivity analysis excluding patients who died within seven days after admission, the results regarding three-month mortality were similar. Another potential confounder could be the difference in ID specialist consultation, because ID consults have been associated with reduced mortality in patients with SAB (5,17-21) . However, multivariate logistic regression analysis did not show this to be an independent predictor of survival, probably due to the high frequency of ID consultation in both groups in the present study. In our study, 18 F-FDG-PET/CT detected endocarditis in 18 patients and was the first imaging technique detecting endocarditis in 11 patients. In contrary, 8 patients were diagnosed with a definite endocarditis according to the modified Duke criteria but had a negative 18 F-FDG-PET/CT. Whether 18 F-FDG-PET/CT could be used for diagnosing native valve endocarditis needs further investigation, as small studies performed on this subject show limited evidence (22) .
Our study has several limitations. First, this is a single-center study that was not prospectively conducted. In 26.6% of patients, 18 F-FDG-PET/CT was indicated but not performed. The reasons for nonadherence to the local guidelines are not known, and this could potentially have led to selection bias. Second, although we used a two-reviewer adjudication process to determine treatment modification, it is possible that misclassification occurred. To reduce bias, the two reviewers were blinded from each other and disagreements were resolved by a third experienced reviewer.
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CONCLUSION
In conclusion, performance of 18 F-FDG-PET/CT is significantly associated with reduced mortality in patients with high-risk SAB, and leads to the detection of metastatic infectious foci in 73.7% of patients, resulting in, important treatment modifications. 18 F-FDG-PET/CT should be recommended as standard imaging technique for all patients with ≥1 risk factor for metastatic infection in SAB guidelines.
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